Octapharma to Present New Data on Management of People with Haemophilia A or von Willebrand Disease at ISTH 2019
2.7.2019 10:38:00 EEST | Business Wire | Press release
New scientific data on Octapharma’s Haematology portfolio will be presented at the upcoming 27th Congress of the International Society on Thrombosis and Haemostasis (ISTH), taking place in Melbourne, Australia, from 6 to 10 July 2019.
Five abstracts have been accepted for poster presentation at the Congress. The presentations include data from real-world experience with Nuwiq® (simoctocog alfa) or octanate® for inhibitor eradication in patients with severe haemophilia A and inhibitors, as well as with wilate® as prophylaxis in patients with von Willebrand disease. In addition, the design and current status of two new studies will be presented: the Protect-NOW study is investigating the use of FVIII in previously untreated and minimally treated haemophilia A patients in a real-life setting, and the MOTIVATE study will document and compare safety and efficacy of ‘standard of care’ ITI with novel ITI approaches combining FVIII with emicizumab, or emicizumab prophylaxis alone, in patients with haemophilia A and inhibitors.
All abstracts are available from the ISTH website (https://www.isth.org/news/457341/ISTH-2019-Abstracts-Now-Available-Online.htm). The titles of the posters, and the date and time of presentation, are provided below.
- Thirteen years of clinical experience with immune tolerance induction (ITI) using a plasma-derived FVIII containing von Willebrand factor (pdFVIII/VWF) in Russia. Poster PB0732, Monday, 8 July 2019, 18:30–19:30
- Safety and efficacy of pdVWF/FVIII in patients with von Willebrand disease undergoing prophylaxis: results from a non-interventional multicentre study. Poster PB0808, Monday, 8 July 2019, 18:30–19:30
- PRactical Utilisation of Octapharma FVIII Concentrates in Previously Untreated and Minimally Treated Haemophilia A Patients Entering Clinical Treatment with Nuwiq®, Octanate® or Wilate® – The Protect-NOW Study. Poster PB1448, Tuesday, 9 July 2019, 18:30–19:30
- Immune Tolerance Induction with Simoctocog Alfa in Nine Patients with Severe Haemophilia A and FVIII Inhibitors. Poster PB1459, Tuesday, 9 July 2019, 18:30–19:30
- MOdern Treatment of Inhibitor-PositiVe PATiEnts with Haemophilia A (MOTIVATE) – an international observational study. Poster PB1406, Tuesday, 9 July 2019, 18:30–19:30
About Octapharma
The vision of Octapharma is: “Our passion drives us to provide new health solutions advancing human life”. Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. As a family-owned company, Octapharma believes in investing to make a difference in people’s lives and has been doing so since 1983; because it’s in our blood. Our company values are Ownership, Integrity, Leadership, Sustainability and Entrepreneurship.
In 2018, the Group achieved €1.8 billion in revenue, an operating income of €346 million and invested €240 million into R&D and in capital expenditures in order to ensure future prosperity. Octapharma employs 8,314 people worldwide to support the treatment of patients in 115 countries with products across three therapeutic areas:
- Haematology (coagulation disorders)
- Immunotherapy (immune disorders)
- Critical care
Octapharma has seven R&D sites and six state-of-the-art manufacturing facilities in Austria, France, Germany, Mexico and Sweden.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190702005197/en/
Contact information
Octapharma AG
International Business Unit - Haematology
Olaf Walter
Olaf.Walter@octapharma.com
Larisa Belyanskaya
Larisa.Belyanskaya@octapharma.com
Tel: +41 55 4512121
Communications Manager
Ivana Spotakova
ivana.spotakova@octapharma.com
tel.: +41793474607
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aga Khan Museum Launches Season 5 of This Being Human as a Multimedia Video Podcast with new host, Mai Habib21.4.2026 16:00:00 EEST | Press release
The highly anticipated launch of Season 5 of This Being Human marks a dynamic new chapter for the Aga Khan Museum’s acclaimed podcast, expanding both its reach and storytelling. Now hosted by former journalist and cultural advocate Mai Habib, the new season brings listeners into compelling dialogue with artists and thought leaders whose work offers a global perspective on art and culture, identity, and new and pressing ideas that shape humanity today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421929514/en/ This Being Human Podcast Logo, Courtesy of the Aga Khan Museum Building on an impressive footprint of more than 100 episodes over the past four seasons, This Being Human will evolve into an audiovisual experience for the first time. Each of the 12 episodes will be filmed and released on YouTube alongside all major podcast platforms, inviting audiences into a more immersive encounter with the voices shaping these co
Aga Khan Museum Launches Season 5 of This Being Human as a Multimedia Video Podcast with new host, Mai Habib21.4.2026 16:00:00 EEST | Press release
The highly anticipated launch of Season 5 of This Being Human marks a dynamic new chapter for the Aga Khan Museum’s acclaimed podcast, expanding both its reach and storytelling. Now hosted by former journalist and cultural advocate Mai Habib, the new season brings listeners into compelling dialogue with artists and thought leaders whose work offers a global perspective on art and culture, identity, and new and pressing ideas that shape humanity today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421929514/en/ This Being Human Podcast Logo, Courtesy of the Aga Khan Museum Building on an impressive footprint of more than 100 episodes over the past four seasons, This Being Human will evolve into an audiovisual experience for the first time. Each of the 12 episodes will be filmed and released on YouTube alongside all major podcast platforms, inviting audiences into a more immersive encounter with the voices shaping these co
Wasabi Technologies Closes $250M Credit Facility to Expand Cloud Storage Innovation21.4.2026 16:00:00 EEST | Press release
Wasabi Technologies, the hot cloud storage company, today announced it has secured a $250 million credit facility led by Bain Capital’s Private Credit Group (“Bain Capital”) with participation from U.S. Private Credit Investments, a division of BTG Pactual Global Alternatives; Neuberger Specialty Finance; Energy Impact Partners; and Aksia. The financing will support continued investment in Wasabi’s cloud storage platform, infrastructure, and broader global expansion. “This is a more selective private lending market, but we’ve built a strong, disciplined business that continues to attract support from leading financial institutions,” said Michael Bayer, EVP and chief financial officer, Wasabi Technologies. “We’re investing in our infrastructure to meet growing demand for data, especially as AI and modern applications require scalable, accessible storage.” The $250M credit facility follows the recent acquisition of Lyve Cloud from Seagate Technology and a $70M equity funding round led by
Wasabi Technologies Closes $250M Credit Facility to Expand Cloud Storage Innovation21.4.2026 16:00:00 EEST | Press release
Wasabi Technologies, the hot cloud storage company, today announced it has secured a $250 million credit facility led by Bain Capital’s Private Credit Group (“Bain Capital”) with participation from U.S. Private Credit Investments, a division of BTG Pactual Global Alternatives; Neuberger Specialty Finance; Energy Impact Partners; and Aksia. The financing will support continued investment in Wasabi’s cloud storage platform, infrastructure, and broader global expansion. “This is a more selective private lending market, but we’ve built a strong, disciplined business that continues to attract support from leading financial institutions,” said Michael Bayer, EVP and chief financial officer, Wasabi Technologies. “We’re investing in our infrastructure to meet growing demand for data, especially as AI and modern applications require scalable, accessible storage.” The $250M credit facility follows the recent acquisition of Lyve Cloud from Seagate Technology and a $70M equity funding round led by
Crown Bioscience and Turbine Partner to Connect AI-Driven Prediction with Organoid Validation in Translational Oncology21.4.2026 15:30:00 EEST | Press release
Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, today announced a strategic partnership with Turbine, a leading virtual biology company, to advance translational oncology research by integrating Turbine’s in silico Virtual Assays with its Tumor Organoid Assays based on HUB Organoid Technology. This collaboration establishes a connected workflow that enables researchers to move more efficiently from hypothesis to validation. Turbine’s Virtual Assays simulate biological response across thousands of biological samples and hundreds of drugs, generating predictive insights to identify and prioritize targets, therapies, and combinations. The predictions will be enhanced through the incorporation of multimodal and drug response data from hundreds of tumor organoid models at Crown Bioscience. Together, the companies create a closed-loop approach linking prediction with validation, improving predictive accuracy, reducing experimental burden, whil
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom